

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this Addendum, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Addendum.

IMPORTANT: Unless otherwise defined herein, words and expressions defined in the circular of GenScript Biotech Corporation dated 29 June 2020 (the “Circular”) shall have the same meaning when used in this Addendum.

If you are in any doubt as to any aspect of this Addendum or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all of your shares in GenScript Biotech Corporation, you should at once hand this Addendum to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Nothing in this Addendum constitutes an offer of securities for sale in the U.S. or any other jurisdictions where it is unlawful to do so. The Distribution ADSs have not been, and will not be, registered under the Securities Act, or the securities laws of any state of the U.S. or other jurisdictions, and the Distribution ADSs may not be offered or sold, directly or indirectly, within the U.S. or to, or for the account or benefit of, U.S. Persons (as defined in Regulation S) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws.

This Addendum may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever and, in particular, may not be forwarded to any U.S. Person or U.S. address. Any forwarding, distribution or reproduction of this Addendum in whole or in part is unauthorised. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.



GenScript Biotech Corporation
金斯瑞生物科技股份有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

ADDENDUM TO CIRCULAR

DISTRIBUTION IN CONNECTION WITH THE SPIN-OFF AND SEPARATE LISTING OF LEGEND BIOTECH CORPORATION ON THE NASDAQ GLOBAL MARKET

CLARIFICATION

Reference is made to the Circular and the accompanying Form of Election of GenScript Biotech Corporation dated 29 June 2020 (the “Circular”).

With respect to Beneficial Owner(s) of Shares whose Shares are registered on the register of members of the Company in the name of HKSCC Nominees Limited in respect of Shares deposited in CCASS, HKSCC Nominees Limited will require such Beneficial Owner(s) to make the requisite certification in Section 1 of the Form of Election in his/her/its own capacity. HKSCC Nominees Limited as a Qualifying Shareholder who is holding Shares in the capacity as a nominee for the account or benefit of such Beneficial Owner(s) will not make such certifications.

Any such Beneficial Owner(s) who wishes to receive Distribution ADSs should contact his/her/its respective Intermediary to make necessary arrangements. Such arrangements should be made in advance of the relevant dates stated in the section headed EXPECTED TIMETABLE in the Circular and otherwise in accordance with the requirements of the Intermediary and/or HKSCC Nominees Limited, in order to allow the Intermediary and/or HKSCC Nominees Limited sufficient time to ensure that any necessary arrangements are given effect.

Save as set out above, there are no changes to the information contained in the Circular.

GENERAL

Qualifying Shareholders and Beneficial Owners are reminded that whether or not it is to their advantage to elect to receive the Distribution in cash payment in lieu of the Distribution ADSs depends on their own individual circumstances and preferences; and the decision in this regard and all effects resulting therefrom are the responsibility of each individual Qualifying Shareholder and Beneficial Owner. The effect on the tax position of any Shareholder will depend on that Shareholder's particular circumstances. Qualifying Shareholders who are trustees are recommended to take professional advice as to whether the choice to receive cash payment or Distribution ADSs is within their power and as to its effect having regard to the terms of the relevant trust instrument.

This Addendum is not, and does not form part of, an offer to sell or solicitation of an offer to purchase or subscribe for any securities of Legend Biotech in Hong Kong, the U.S. or any other jurisdictions, and this Addendum, or any part of it, shall not form the basis of, or be relied on in connection with, any investment decision relating to any securities of Legend Biotech.

If you are in any doubt as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

Yours faithfully
Zhang Fangliang
Chairman and Chief Executive Officer

Nanjing, People's Republic of China
29 June 2020

As at the date of this announcement, the executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye and Mr. MENG Jiange; the non-executive Directors are Dr. WANG Luquan, Mr. PAN Yuexin and Ms. WANG Jiafen; and the independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian and Mr. PAN Jiuan.

* *For identification purposes only*